Tectonic Therapeutic, Inc. engages in the discovery of antibodies and other biologic drugs targeting G-protein-coupled receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. It offers a GEODe platform to overcome the challenges encountered to date in GPCR biologic discovery campaigns and enables the advancement of novel GPCR-targeting therapies. Tectonic Therapeutic, Inc. was incorporated in 2019 and is based in Watertown, Massachusetts.
Page last updated on:
July 6th, 2024
Categories: